Filtered By:
Infectious Disease: Genital Warts
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 304 results found since Jan 2013.
Cancers, Vol. 15, Pages 4405: Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Larynx: A Scoping Review of Treatment Guidelines Worldwide
Maria Paula Curado
Head and neck cancer (HNC) treatments have been based on single or multimodal therapies with surgery, radiotherapy (RT), chemotherapy, and immunotherapy. However, treatment recommendations among countries may differ due to technological/human resources and usual local practices. This scoping review aims to identify, compare, and map the clinical practice guidelines (CPGs) for treating squamous cell carcinoma (SCC) of the oral cavity, oropharynx, and larynx worldwide. A search strategy on global CPGs for HNC was performed by using five electronic databases and grey literature. CPGs were selected for ...
Source: Cancers - September 3, 2023 Category: Cancer & Oncology Authors: Lady Paola Aristizabal Arboleda Genival Barbosa de Carvalho Alan Roger Santos-Silva Gisele Aparecida Fernandes Jose Guilherme Vartanian David I. Conway Shama Virani Paul Brennan Luiz Paulo Kowalski Maria Paula Curado Tags: Systematic Review Source Type: research
Tumor cell p38 inhibition to overcome immunotherapy resistance
Res Sq. 2023 Aug 19:rs.3.rs-3183496. doi: 10.21203/rs.3.rs-3183496/v1. Preprint.ABSTRACTPatients with tumors that do not respond to immune-checkpoint inhibition often harbor a non-T cell-inflamed tumor microenvironment, characterized by the absence of IFN-γ-associated CD8+ T cell and dendritic cell activation. Understanding the molecular mechanisms underlying immune exclusion in non-responding patients may enable the development of novel combination therapies. p38 MAPK is a known regulator of dendritic and myeloid cells however a tumor-intrinsic immunomodulatory role has not been previously described. Here we identify tum...
Source: Cell Research - August 30, 2023 Category: Cytology Authors: Jason Luke Rebekah Dadey Ryan Augustin Sarah Newman Krishna Singh Rose Doerfler Sarah Behr Patrice Lee Brian Isett Christopher Deitrick Aofei Li Marion Joy Carly Reeder Katelyn Smith Julie Urban Lorenzo Sellitto Mark Jelinek Susan Christner Jan Beumer Liz Source Type: research
Virus-associated neuroendocrine cancers: Pathogenesis and current therapeutics
Pathol Res Pract. 2023 Jul 27;248:154720. doi: 10.1016/j.prp.2023.154720. Online ahead of print.ABSTRACTNeuroendocrine neoplasms (NENs) comprise malignancies involving neuroendocrine cells that often lead to fatal pathological conditions. Despite escalating global incidences, NENs still have poor prognoses. Interestingly, research indicates an intricate association of tumor viruses with NENs. However, there is a dearth of comprehension of the complete scenario of NEN pathophysiology and its precise connections with the tumor viruses. Interestingly, several cutting-edge experiments became helpful for further screening of NE...
Source: Pathology, Research and Practice - August 5, 2023 Category: Pathology Authors: Juni Banerjee Ramya P Ranjan Md Tanjim Alam Sanika Deshmukh Prem Prakash Tripathi Sonu Gandhi Shuvomoy Banerjee Source Type: research
Dual anti-PD-(L)1/TGF- β inhibitors in cancer immunotherapy - Updated
Int Immunopharmacol. 2023 Jul 15;122:110648. doi: 10.1016/j.intimp.2023.110648. Online ahead of print.ABSTRACTImmune checkpoint inhibitor (ICI) therapy suffers from tumor resistance and relapse in majority of patients due to the suppressive tumor immune microenvironment (TIME). Advances in the field have brought about development of fusion proteins able to target two signaling simultaneously and to exert maximal anti-cancer immunity. Bispecific inhibitors of transforming growth factor (TGF)-β signaling and programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are developed to reduce the rate of relapse and to ach...
Source: International Immunopharmacology - July 17, 2023 Category: Allergy & Immunology Authors: Zana Karami Keywan Mortezaee Jamal Majidpoor Source Type: research
Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction
This article's main highlight is discussing the drug targets of SUDs and their associated mechanisms. Importantly, we have also discussed the scope of prophylactic measures to eliminate drug dependence.PMID:37099943 | DOI:10.1016/j.intimp.2023.110210
Source: International Immunopharmacology - April 26, 2023 Category: Allergy & Immunology Authors: Jonaid Ahmad Malik Javed N Agrewala Source Type: research
Advances in immunotherapy for cervical cancer
Ther Adv Med Oncol. 2023 Mar 28;15:17588359231163836. doi: 10.1177/17588359231163836. eCollection 2023.ABSTRACTCervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an human papillomavirus-related malignancy, is a largely preventable disease by means of well-established screening and vaccination programs. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches represent a dismal prognosis population. Until recently, these patient...
Source: Adv Data - April 3, 2023 Category: Epidemiology Authors: Juan Francisco Grau-Bejar Carmen Garcia-Duran David Garcia-Illescas Oriol Mirallas Ana Oaknin Source Type: research
Fecal Microbiota Transplantation as a Cancer Therapeutic
Cancer J. 2023 Mar-Apr 01;29(2):102-108. doi: 10.1097/PPO.0000000000000651.ABSTRACTFor decades, cancer research and treatment focused on the cellular level, viewing cancer as a genetic disease of cell transformation. In the era of chemotherapy and radiotherapy, studies from the second half of the 19th century suggesting an association between the microbiota and cancer were almost neglected. The main focus of the field was limited to identification of specific viruses and bacteria that may serve as direct carcinogens leading to the recognition of 7 viruses (i.e., human papillomavirus, hepatitis B virus, and Kaposi sarcoma-a...
Source: Cancer Journal - March 23, 2023 Category: Cancer & Oncology Authors: Ronen Stoff Yochai Wolf Ben Boursi Source Type: research
